Aberrant Splicing and Drug Resistance in AML

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2016 Sep 11

PMID 27613060

Citations 34

Authors

Rosalia de Necochea-Campion

Geoffrey P Shouse

Qi Zhou

Saied Mirshahidi

Chien-Shing Chen

Affiliations

Soon will be listed here.

Abstract

The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease. This review will focus on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated oncogenic targets.

Citing Articles

Biological relevance of alternative splicing in hematologic malignancies.

Szelest M, Giannopoulos K Mol Med. 2024; 30(1):62.

PMID: 38760666 PMC: 11100220. DOI: 10.1186/s10020-024-00839-2.

Alternative Splicing Events and Their Clinical Significance in Colorectal Cancer: Targeted Therapeutic Opportunities.

Manabile M, Hull R, Khanyile R, Molefi T, Damane B, Mongan N Cancers (Basel). 2023; 15(15).

PMID: 37568815 PMC: 10417810. DOI: 10.3390/cancers15153999.

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.

Morales M, Garcia-Vicente R, Rodriguez-Garcia A, Reyes-Palomares A, Vincelle-Nieto A, Alvarez N Leukemia. 2023; 37(8):1649-1659.

PMID: 37422594 PMC: 10400425. DOI: 10.1038/s41375-023-01963-4.

SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia.

Wodi C, Belali T, Morse R, Porazinski S, Ladomery M Br J Biomed Sci. 2023; 80:11041.

PMID: 36895328 PMC: 9988938. DOI: 10.3389/bjbs.2023.11041.

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.

Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J, Gendron P, Skrabanek L EMBO J. 2023; 42(7):e110496.

PMID: 36843541 PMC: 10068332. DOI: 10.15252/embj.2021110496.

References

Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-76. PMC: 4342352. DOI: 10.1182/blood-2014-11-610543. View

Wang H, Wen J, Chang C, Zhou X . Discovering transcription and splicing networks in myelodysplastic syndromes. PLoS One. 2013; 8(11):e79118. PMC: 3828332. DOI: 10.1371/journal.pone.0079118. View

Ilagan J, Ramakrishnan A, Hayes B, Murphy M, Zebari A, Bradley P . U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2014; 25(1):14-26. PMC: 4317169. DOI: 10.1101/gr.181016.114. View

Mohamed A, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M . Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget. 2015; 7(3):2889-909. PMC: 4823079. DOI: 10.18632/oncotarget.3898. View

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View

Wagner M, Schmelz K, Wuchter C, Ludwig W, Dorken B, Tamm I . In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer. 2006; 119(6):1291-7. DOI: 10.1002/ijc.21995. View

Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez G . Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS One. 2015; 10(9):e0138377. PMC: 4573975. DOI: 10.1371/journal.pone.0138377. View

Renshaw S, Dempsey C, Barnes F, Bagstaff S, Dower S, Bingle C . Three novel Bid proteins generated by alternative splicing of the human Bid gene. J Biol Chem. 2003; 279(4):2846-55. DOI: 10.1074/jbc.M309769200. View

Mohamed A, Thenoz M, Solly F, Balsat M, Mortreux F, Wattel E . How mRNA is misspliced in acute myelogenous leukemia (AML)?. Oncotarget. 2014; 5(20):9534-45. PMC: 4259418. DOI: 10.18632/oncotarget.2304. View

10.

Bonnal S, Vigevani L, Valcarcel J . The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012; 11(11):847-59. DOI: 10.1038/nrd3823. View

11.

Vo T, Ryan J, Carrasco R, Neuberg D, Rossi D, Stone R . Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012; 151(2):344-55. PMC: 3534747. DOI: 10.1016/j.cell.2012.08.038. View

12.

Grech G, Pollacco J, Portelli M, Sacco K, Baldacchino S, Grixti J . Expression of different functional isoforms in haematopoiesis. Int J Hematol. 2013; 99(1):4-11. DOI: 10.1007/s12185-013-1477-7. View

13.

Webb T, Joyner A, Potter P . The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today. 2012; 18(1-2):43-9. PMC: 3596818. DOI: 10.1016/j.drudis.2012.07.013. View

14.

Shultz J, Goehe R, Wijesinghe D, Murudkar C, Hawkins A, Shay J . Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 2010; 70(22):9185-96. PMC: 3059118. DOI: 10.1158/0008-5472.CAN-10-1545. View

15.

Zinkel S, Ong C, Ferguson D, Iwasaki H, Akashi K, Bronson R . Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev. 2003; 17(2):229-39. PMC: 195974. DOI: 10.1101/gad.1045603. View

16.

Chen H, Cheng S . Functional roles of protein splicing factors. Biosci Rep. 2012; 32(4):345-59. PMC: 3392075. DOI: 10.1042/BSR20120007. View

17.

Krueger A, Schmitz I, Baumann S, Krammer P, Kirchhoff S . Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001; 276(23):20633-40. DOI: 10.1074/jbc.M101780200. View

18.

Ng K, Hillmer A, Chuah C, Juan W, Ko T, Teo A . A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4):521-8. DOI: 10.1038/nm.2713. View

19.

Brown-Bryan T, Leoh L, Ganapathy V, Pacheco F, Mediavilla-Varela M, Filippova M . Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75. Mol Cancer Res. 2008; 6(8):1293-307. PMC: 2790462. DOI: 10.1158/1541-7786.MCR-08-0125. View

20.

Hatakeyama K, Yamakawa Y, Fukuda Y, Ohshima K, Wakabayashi-Nakao K, Sakura N . A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells. Gastric Cancer. 2014; 18(4):751-61. DOI: 10.1007/s10120-014-0426-3. View